Hematologic disorders associated with hepatitis C virus infection and their management

被引:68
作者
Dieterich, DT
Spivak, JL
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[2] Johns Hopkins Med Inst, Div Hematol, Baltimore, MD 21205 USA
关键词
D O I
10.1086/376971
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20 - 30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon (IFN)-alpha or pegylated IFN-alpha and ribavirin. For a sustained virologic response, treatment adherence and dose maintenance are essential. However, both IFN-alpha and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially influence outcomes. Although there are currently no approved treatments for hematologic complications of HCV therapy, studies have shown that hematopoietic growth factors can provide significant benefits. This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients.
引用
收藏
页码:533 / 541
页数:9
相关论文
共 92 条
  • [41] Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
    Lai, MY
    Kao, JH
    Yang, PM
    Wang, JT
    Chen, PJ
    Chan, KW
    Chu, JS
    Chen, DS
    [J]. GASTROENTEROLOGY, 1996, 111 (05) : 1307 - 1312
  • [42] A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
    Lindsay, KL
    Trepo, C
    Heintges, T
    Shiffman, ML
    Gordon, SC
    Hoefs, JC
    Schiff, ER
    Goodman, ZD
    Laughlin, M
    Yao, RJ
    Albrecht, JK
    [J]. HEPATOLOGY, 2001, 34 (02) : 395 - 403
  • [43] Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
    Littlewood, TJ
    Bajetta, E
    Nortier, JWR
    Vercammen, E
    Rapoport, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) : 2865 - 2874
  • [44] Maddrey WC, 1999, SEMIN LIVER DIS, V19, P67
  • [45] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    Manns, MP
    McHutchison, JG
    Gordon, SC
    Rustgi, VK
    Shiffman, M
    Reindollar, R
    Goodman, ZD
    Koury, K
    Ling, MH
    Albrecht, JK
    [J]. LANCET, 2001, 358 (9286) : 958 - 965
  • [46] Hepatitis C advances in antiviral therapy: What is accepted treatment now?
    McHutchison, JG
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (04) : 431 - 441
  • [47] Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
    McHutchison, JG
    Gordon, SC
    Schiff, ER
    Shiffman, ML
    Lee, WM
    Rustgi, VK
    Goodman, ZD
    Ling, MH
    Cort, S
    Albrecht, JK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) : 1485 - 1492
  • [48] Adherence to combination therapy enhances sustained response in genotyp-1-infected patients with chronic hepatitis C
    McHutchison, JG
    Manns, M
    Patel, K
    Poynard, T
    Lindsay, KL
    Trepo, C
    Dienstag, J
    Lee, WM
    Mak, C
    Garaud, JJ
    Albrecht, JK
    [J]. GASTROENTEROLOGY, 2002, 123 (04) : 1061 - 1069
  • [49] McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57
  • [50] Moccia F, 2001, Ann Ital Med Int, V16, P256